Genetically determined sparteine oxidation polymorphism in a Polish population
✍ Scribed by K. Orzechowska-Juzwenko; J. Pawlik; P. Niewiński; P. Milejski; J. Dembowski; J. Turek; A. Goździk; L. Swiebodzki; Z. Hora
- Publisher
- Springer
- Year
- 1994
- Tongue
- English
- Weight
- 259 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
✦ Synopsis
The genetic oxidation polymorphism was determined in 160 healthy Polish volunteers from the southwest of Poland (Wroctaw region), using sparteine as a model drug. The results of a Polish population study revealed a bimodal distribution of the sparteine metabolic ratio and showed the existence of two oxidation phenotypes designated as extensive and poor metabolizers. The frequency of poor metabolizers in our study (8.8 %) compares well with most results of poor oxidation metabolizers in Caucasian populations.
📜 SIMILAR VOLUMES
The debrisoquine hydroxylation phenotype was studied in 152 unselected healthy Tasmanian subjects, who were mostly Caucasians of British ancestry. Following a 10 mg oral dose of debrisoquine (D), the ratio of D/4-hydroxydebrisoquine excreted in 8-h urine (metabolic ratio, MR) was determined. MR valu
The wide availability, metabolism by the same cytochrome P450 as debrisoquine and, above all, the inocuity of dextromethorphan (DMP) favour the frequent choice of this drug as the test substance in determining oxidation phenotypes. 100 healthy Burundian volunteers (94 m and 6 f) in this study ingest
The plasma concentration and cumulative urinary excretion over 34h of dextromethorphan, free and conjugated dextrorphan, and 3-hydroxymorphinan were determined in seven healthy Japanese subjects after oral administration of 30mg dextromethorphan hydrobromide. Conjugated metabolites were extensively